Welcome to our dedicated page for Avita Medical SEC filings (Ticker: AVHHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avita Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avita Medical's regulatory disclosures and financial reporting.
O'Toole David D reported acquisition or exercise transactions in this Form 4 filing.
AVITA Medical CFO David D. O'Toole received a grant of 2,000 shares of common stock at a reference value of $3.97 per share. This was a compensation-related award, not an open-market purchase, and increased his directly held stake to 152,927 shares, including unvested RSUs.
O'Toole David D reported acquisition or exercise transactions in this Form 4 filing.
AVITA Medical CFO David D. O'Toole received a grant of 2,000 shares of common stock at a reference value of $3.97 per share. This was a compensation-related award, not an open-market purchase, and increased his directly held stake to 152,927 shares, including unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin made an open-market purchase of the company’s common stock. On June 9, 2026, he bought 5,200 shares at $4.00 per share, bringing his direct holdings to 107,961 shares, which the disclosure notes include unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin made an open-market purchase of the company’s common stock. On June 9, 2026, he bought 5,200 shares at $4.00 per share, bringing his direct holdings to 107,961 shares, which the disclosure notes include unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of common stock in open-market transactions. The purchases occurred at prices of $4.18 and $4.20 per share. A footnote indicates the reported holdings include unvested restricted stock units (RSUs).
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of common stock in open-market transactions. The purchases occurred at prices of $4.18 and $4.20 per share. A footnote indicates the reported holdings include unvested restricted stock units (RSUs).
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of the company’s Common Stock in open-market transactions. The purchases on June 3, 2026 were made at prices of $4.0899 and $4.0999 per share.
After these trades, Fralin directly holds 92,761 shares of AVITA Medical common stock, which the disclosure notes includes unvested restricted stock units (RSUs). These are straightforward open-market purchases, increasing his direct equity stake in the company.
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of the company’s Common Stock in open-market transactions. The purchases on June 3, 2026 were made at prices of $4.0899 and $4.0999 per share.
After these trades, Fralin directly holds 92,761 shares of AVITA Medical common stock, which the disclosure notes includes unvested restricted stock units (RSUs). These are straightforward open-market purchases, increasing his direct equity stake in the company.
AVITA Medical, Inc. director Robert McNamara reported receiving new equity compensation. He was granted 22,214 restricted stock units, each representing one share of common stock, subject to time-based vesting. These RSUs vest 12 months after the January 20, 2026 grant date, following stockholder approval obtained on June 3, 2026.
McNamara was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. The options were approved by the board on January 5, 2026, have a grant date of January 20, 2026, become exercisable starting January 20, 2027, and expire on January 20, 2036. Following these awards, he directly owns 108,985 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. director Robert McNamara reported receiving new equity compensation. He was granted 22,214 restricted stock units, each representing one share of common stock, subject to time-based vesting. These RSUs vest 12 months after the January 20, 2026 grant date, following stockholder approval obtained on June 3, 2026.
McNamara was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. The options were approved by the board on January 5, 2026, have a grant date of January 20, 2026, become exercisable starting January 20, 2027, and expire on January 20, 2036. Following these awards, he directly owns 108,985 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin. On January 5, 2026, he received 40,547 restricted stock units (RSUs) and 29,446 stock options with a $3.47 exercise price, subject to stockholder approval obtained on June 3, 2026. On January 20, 2026, he received an additional 22,214 RSUs and 16,133 stock options with a $3.77 exercise price. The RSUs vest over time, and the options vest in three equal annual installments, providing long-term, stock-based compensation. Following these awards, his direct common stock holdings increased to 82,761 shares.
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin. On January 5, 2026, he received 40,547 restricted stock units (RSUs) and 29,446 stock options with a $3.47 exercise price, subject to stockholder approval obtained on June 3, 2026. On January 20, 2026, he received an additional 22,214 RSUs and 16,133 stock options with a $3.77 exercise price. The RSUs vest over time, and the options vest in three equal annual installments, providing long-term, stock-based compensation. Following these awards, his direct common stock holdings increased to 82,761 shares.
AVITA Medical, Inc. director Michael E. Tarnoff reported equity awards in the form of restricted stock units (RSUs) and stock options. On August 6, 2025, he received 26,250 RSUs and 19,063 stock options with an exercise price of $5.36 per share, vesting in three equal annual installments after the first anniversary. On January 20, 2026, he received an additional 22,214 RSUs that vest 12 months after the grant date and 16,133 stock options with an exercise price of $3.77 per share, also vesting in three equal annual installments beginning one year after grant. These awards were approved by the Board and were subject to stockholder approval obtained on June 3, 2026. Following the most recent RSU grant, Tarnoff directly holds 48,464 shares of common stock.
AVITA Medical, Inc. director Michael E. Tarnoff reported equity awards in the form of restricted stock units (RSUs) and stock options. On August 6, 2025, he received 26,250 RSUs and 19,063 stock options with an exercise price of $5.36 per share, vesting in three equal annual installments after the first anniversary. On January 20, 2026, he received an additional 22,214 RSUs that vest 12 months after the grant date and 16,133 stock options with an exercise price of $3.77 per share, also vesting in three equal annual installments beginning one year after grant. These awards were approved by the Board and were subject to stockholder approval obtained on June 3, 2026. Following the most recent RSU grant, Tarnoff directly holds 48,464 shares of common stock.
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation. He received 22,214 RSUs, each representing one share of common stock, which are subject to time-based vesting 12 months after the January 20, 2026 grant date and were approved by stockholders on June 3, 2026. He also received options to acquire 16,133 shares of common stock at an exercise price of $3.77 per share, exercisable starting January 20, 2027 and expiring January 20, 2036. Following the RSU award, his direct common stock holdings, including unvested RSUs, total 62,050 shares, and he holds 16,133 stock options.
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation. He received 22,214 RSUs, each representing one share of common stock, which are subject to time-based vesting 12 months after the January 20, 2026 grant date and were approved by stockholders on June 3, 2026. He also received options to acquire 16,133 shares of common stock at an exercise price of $3.77 per share, exercisable starting January 20, 2027 and expiring January 20, 2036. Following the RSU award, his direct common stock holdings, including unvested RSUs, total 62,050 shares, and he holds 16,133 stock options.
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.
On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.
On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.